Study of blinatumomab injection for a rare leukemia type
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new way to give blinatumomab (a drug that helps your immune system fight cancer) as a shot under the skin for a rare leukemia called MPAL. It includes three different groups of patients depending on their treatment history.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be diagnosed with a specific type of leukemia called MPAL that has a protein called CD19.
- You must be willing to come to the clinic for study visits and follow study rules.
- You must not have a serious, uncontrolled infection or be taking other cancer treatments (like chemotherapy or radiation) at the same time.
- Based on which group you fit into, you may need to be older or have health conditions that prevent strong chemo, have had at least one prior treatment, or have leukemia that returned after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a subcutaneous (under the skin) form of blinatumomab for people with B-cell acute lymphoblastic leukemia who are in remission but still have tiny amounts of leukemia cells that can be detected by sensitive tests. The goal is to see if this treatment is safe and can get rid of those remaining cells.
This trial tests a combination of immune-targeted therapy plus chemotherapy for people with a rare type of leukemia that doesn't clearly fit into the usual categories. The goal is to see if this approach can help control the leukemia better.
This trial tests a combination of two drugs, inotuzumab and blinatumomab, for people with B-cell acute lymphoblastic leukemia (B-ALL). It may be an option for newly diagnosed patients who are older or unable to tolerate standard chemotherapy, or for patients whose leukemia has returned or not responded to treatment.
This trial tests if a shot (subcutaneous) form of blinatumomab works as well as the standard IV (drip) form for adults newly diagnosed with a type of leukemia called B-cell acute lymphoblastic leukemia (ALL). It aims to see if the shot is more convenient and just as effective.
This trial tests a drug called blinatumomab for people with B-ALL whose leukemia has come back at a very low level (detected only by sensitive testing) after a stem cell transplant. The goal is to see if blinatumomab can clear these remaining leukemia cells and prevent a full relapse.
This trial tests two new drug combinations for a specific type of blood cancer called B-cell acute lymphoblastic leukemia (ALL) that has a genetic change called KMT2A-rearrangement. The goal is to help patients who are at higher risk of their cancer coming back after initial treatment.
Hear when a new CD19 Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.